Drug discovery in renin-angiotensin system intervention: Past and future

Therapeutic Advances in Cardiovascular Disease

Volumn 10, Issue 3, 2016, Pages 118-125

  Williams, Bryan ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

angiotensin II; cardiovascular remodelling; renin angiotensin system (RAS)

Indexed keywords

ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN INHIBITOR; VALSARTAN; RENIN;

BLOOD PRESSURE REGULATION; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; HEART PROTECTION; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; DRUG DEVELOPMENT; DRUG EFFECTS; HYPERTENSION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84976342625     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944716642680     Document Type: Conference Paper

References (46)

1. Ambuhl P., Tissot A., Fulurija A., Maurer P., Nussberger J., Sabat R., et al.(2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25: 63-72.
2. AstraZeneca (1998) Atacand® (candesartan cilexetil) prescribing information. Wilmingont, DE: AstraZeneca.
3. Bakhle Y., Reynard A., Vane J., (1969) Metabolism of the angiotensins in isolated perfused tissues. Nature 222: 956-959.
4. Bloch M., Basile J., (2010) Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone. J Clin Hypertens 12: 809-812.
5. Bosnyak S., Welungoda I., Hallberg A., Alterman M., Widdop R., Jones E., (2010) Stimulation of angiotensin AT2 receptors by the non-peptide agonist, compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 159: 709-716.
6. Braun-Menendez E., Fasciolo J., Leloir L., Muñoz J., (1940) The substance causing renal hypertension. J Physiol 98: 283-298.
7. Bumpus F., Schwarz H., Page I., (1957) Synthesis and pharmacology of the octapeptide angiotonin. Science 125: 886-887.
8. Cheung B., (2010) The hypertension-diabetes continuum. J Cardiovasc Pharmacol 55: 333-339.
9. Cohn J., Tognoni G., (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675.
10. Cushman D., Cheung H., Sabo E., Rubin B., Ondetti M., (1979) Development of specific inhibitors of angiotensin I converting enzyme (kininase II). Fed Proc 38: 2778-2782.
11. Cushman D., Ondetti M., Cheung H., Antonaccio M., Murthy V., Rubin B., (1980) Inhibitors of angiotensin-converting enzyme. Adv Exp Med Biol 130: 199-225.
12. Cushman D., Pluscec J., Williams N., Weaver E., Sabo E., Kocy O., et al.(1973) Inhibition of angiotensin-coverting enzyme by analogs of peptides from Bothrops jararaca venom. Experientia 29: 1032-1035.
13. D'agostino R., Sr, Massaro J., Sullivan L., (2003) Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med 22: 169-186.
14. Elliott W., Meyer P., (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201-207.
15. Ferreira S., Greene L., Alabaster V., Bakhle Y., Vane J., (1970) Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 225: 379-380.
16. Fournier D., Luft F., Bader M., Ganten D., Andrade-Navarro M., (2012) Emergence and evolution of the renin-angiotensin-aldosterone system. J Mol Med 90: 495-508.
17. Goldblatt H., Lynch J., Hanzal R., Summerville W., (1934) Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59: 347-379.
18. Gross F., (1958) Renin und Hypertensin, physiologische oder pathologische Wirkstoffe? Klin Wschr 36: 693.
19. Gu J., Noe A., Chandra P., Al-Fayoumi S., Ligueros-Saylan M., Sarangapani R., et al.(2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNI). J Clin Pharmacol 50: 401-414.
20. Hermida R., Ayala D., Khder Y., Calvo C., (2008) Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther 30: 108-120.
21. James P., Oparil S., Carter B., Cushman W., Dennison-Himmelfarb C., Handler J., et al.(2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507-520.
22. Kaschina E., Grzesiak A., Li J., Foryst-Ludwig A., Timm M., Rompe F., et al.(2008) Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118: 2523-2532.
23. Maggioni A., Anand I., Gottlieb S., Latini R., Tognoni G., Cohn J., (2002) Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40: 1414-1421.
24. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al.(2014) 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 23: 3-16.
25. McMurray J., Packer M., Desai A., Gong J., Lefkowitz M., Rizkala A., et al.(2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993-1004.
26. Motley E., Eguchi K., Gardner C., Hicks A., Reynolds C., Frank G., et al.(2003) Insulin-induced AKT activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension 41: 775-780.
27. Mylan Pharmaceuticals (2015) Captopril prescribing information. Canonsburg, PA: Mylan Pharmaceuticals Inc.
28. Novartis (1996) Diovan (valsartan) prescribing information. East Hanover, NJ: Novartis.
29. Novartis (2015) Tekturna (Aliskiren) prescribing information. East Hanover, NJ: Novartis.
30. Page I., Helmer O., (1940) A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J Exp Med 71: 29-42.
31. Parving H., Brenner B., McMurray J., De Zeeuw D., Haffner S., Solomon S., et al.(2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213.
32. Pfeffer M., McMurray J., Velazquez E., Rouleau J., Kober L., Maggioni A., et al.(2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906.
33. Rehman A., Leibowitz A., Yamamoto N., Rautureau Y., Paradis P., Schiffrin E., (2012) Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59: 291-299.
34. Rittel W., Iselin I., Kappeler H., Riniker B., Schwyzer R., (1957) Synthese eines hochwirksamen hypertensin II-amids. Helv Chim Acta 40: 614-624.
35. Rompe F., Artuc M., Hallberg A., Alterman M., Stroder K., Thone-Reineke C., et al.(2010) Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55: 924-931.
36. Schmieder R., Hilgers K., Schlaich M., Schmidt B., (2007) Renin-angiotensin system and cardiovascular risk. Lancet 369: 1208-1219.
37. Sironi A., Gastaldelli A., Mari A., Ciociaro D., Positano V., Buzzigoli E., et al.(2004) Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 44: 127-133.
38. Skeggs L., Dorer F., Kahn J., Lentz K., Levine M., (1976) The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med 60: 737-748.
39. Skeggs L. Jr., Marsh W., Kahn J., Shumway N., (1954a) The existence of two forms of hypertensin. J Exp Med 99: 275-282.
40. Skeggs L. Jr., Marsh W., Kahn J., Shumway N., (1954b) The purification of hypertensin I. J Exp Med 100: 363-370.
41. Skeggs L. Jr., Marsh W., Kahn J., Shumway N., (1955) Amino acid composition and electrophoretic properties of hypertensin I. J Exp Med 102: 435-440.
42. Smith D., (2002) Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. Am J Hypertens 15: 108s-114s.
43. Tigerstedt R., Bergman P., (1898) Niere und kreislauf. Skandinavisches Archiv Physiolgie 8: 223-271.
44. Unger T., Dahlof B., (2010) Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential. J Renin-angiotensin Aldosterone Syst 11: 75-77.
45. Williams B., Cockcroft J., Kario K., Zappe D., Cardenas P., Hester A., et al.(2014) Rationale and study design of the prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker measuring arterial stiffness in the elderly (PARAMETER) study. BMJ Open 4: e004254.
46. Yusuf S., Teo K., Pogue J., Dyal L., Copland I., Schumacher H., et al.(2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.